Germline and somatic testing for homologous repair deficiency in patients with prostate cancer (part 1 of 2).

Autor: Armstrong AJ; Duke Cancer Institute Center for Prostate and Urologic Cancers, Duke University Medical Center, Durham, NC, USA., Taylor A; University of Wisconsin, Madison, WI, USA., Haffner MC; Fred Hutchinson Cancer Center, Seattle, WA, USA., Abida W; Memorial Sloan Kettering Cancer Center, New York, NY, USA., Bryce AH; City of Hope, Goodyear, AZ, USA., Karsh LI; The Urology Center of Colorado, Denver, CO, USA., Tagawa ST; Weill Cornell Medicine, New York, NY, USA., Twardowski P; Saint John's Cancer Institute, Santa Monica, CA, USA., Serritella AV; University of Wisconsin, Madison, WI, USA., Lang JM; University of Wisconsin, Madison, WI, USA. jmlang@medicine.wisc.edu.
Jazyk: angličtina
Zdroj: Prostate cancer and prostatic diseases [Prostate Cancer Prostatic Dis] 2024 Oct 01. Date of Electronic Publication: 2024 Oct 01.
DOI: 10.1038/s41391-024-00901-4
Abstrakt: Background/objectives: Unfortunately, not all metastatic castration resistant prostate cancer (mCRPC) patients receive available life-prolonging systemic therapies, emphasizing the need to optimize mCRPC treatment selections. Better guidelines are necessary to determine genetic testing in prostate cancer.
Subjects/methods: In this two-part expert opinion-based guide, we provide an expert consensus opinion on the utilization of germline and somatic testing to detect HRR alterations in patients with mCRPC. This guide was developed by a multidisciplinary expert panel that convened in 2023-2024, including representatives from medical oncology, urology, radiation oncology, pathology, medical genomics, and basic science.
Results/conclusion: We argue for the widespread adoption of germline testing in all patients with prostate cancer and for somatic mutations testing in patients at the time of recurrent/metastatic disease. In this first part, we review how genomic testing is performed. We also review how to overcome certain barriers to integrate genetic and biomarker testing into clinical practice.
(© 2024. The Author(s).)
Databáze: MEDLINE
Externí odkaz: